GLTO
Galecto, Inc. [GLTO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GLTO Stock Summary
In the News
GLTO Financial details
Company Rating
-
Market Cap
18.46M
Income
-37.79M
Revenue
1.2M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
-0.44
Forward P/E
-
PEG
0.11
P/S
-
P/B
0.54
P/C
-
P/FCF
-0.55
Quick Ratio
3.61
Current Ratio
3.75
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.43
EPS next Y
-
EPS next Q
-
EPS this Y
-40.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20%
-
-
-
-
SMA20
-12%
SMA50
-15.38%
SMA100
-12%
Inst Own
-
Inst Trans
-
ROA
-92%
ROE
-95%
ROC
-1.25%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5-3.7
52W High
-
52W Low
-
RSI
47
Rel Volume
-
Avg Volume
231.47K
Volume
609
Perf Week
4.81%
Perf Month
-9.63%
Perf Quarter
1.51%
Perf Half Y
-26.82%
-
-
-
-
Beta
1.246
-
-
Volatility
0.89%, 1.79%
Prev Close
-4.39%
Price
21.58
Change
-3.19%
Company Profile
- Volume Average 231.47K
- Market Capitalization 18.46M
- Employee 13
- CEO Dr. Hans T. Schambye M.D., Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2020-10-29
-
Website
https://galecto.com 
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
